Blueprint Medicines Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '24 Sep 30, 2024	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	0.02	0.02	0.01	0.02
Revenue Growth (YoY)	38.74%	36.86%	-17.34%	-
Cost of Revenue	0.02	0.02	0	0.01
Gross Profit	0	0	0.01	0.01
Selling, General & Admin	0.15	0.14	0.12	0.08
Operating Expenses	0.2	0.19	0.15	0.08
Operating Income	-0.19	-0.19	-0.14	-0.07
Interest Expense	-0.03	-0.04	-0.05	-0.08
EBT Excluding Unusual Items	-0.22	-0.22	-0.19	-0.15
Other Unusual Items	-	-	0	-
Pretax Income	-0.22	-0.22	-0.19	-0.15
Net Income	-0.22	-0.22	-0.19	-0.15
Net Income to Common	-0.22	-0.22	-0.19	-0.15
Shares Outstanding (Basic)	292	282	254	-
Shares Outstanding (Diluted)	292	282	254	-
Shares Change (YoY)	14.97%	11.23%	-	-
EPS (Basic)	-0.00	-0.00	-0.00	-
EPS (Diluted)	-0.00	-0.00	-0.00	-
Gross Margin	6.48%	5.89%	75.90%	43.89%
Operating Margin	-1012.10%	-980.70%	-979.09%	-415.80%
Profit Margin	-1157.76%	-1166.47%	-1354.03%	-905.77%
EBITDA	-0.15	-0.14	-0.11	-
D&A For EBITDA	0.04	0.04	0.03	-
EBIT	-0.19	-0.19	-0.14	-0.07

Source: S&P Global Market Intelligence. Standard template. Financial Sources.